TORONTO, Nov. 27, 2013 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"),
an emerging pharmaceutical company, today announced that the Company's
President and Chief Executive Officer, David Lickrish, will present at
the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel
in New York City. Highland's presentation is scheduled for Wednesday,
December 4, 2013 at 2:10pm EST.
A live webcast of the presentation can be accessed by visiting www.highlandtherapeutics.com. The webcast will be archived on the Company's website for 30 days.
Mr. Lickrish will provide the investment community with an update on the
clinical development of HLD-200, Highland's novel formulation of
methylphenidate for the treatment of Attention-Deficit/Hyperactivity
Disorder (ADHD). HLD-200 is designed to be taken at bedtime, to provide
clinically meaningful control of symptoms of ADHD upon wakening and
throughout the day.
Highland intends to request an End-of-Phase 2 meeting with the U.S. Food
and Drug Administration (FDA) prior to year-end. Based on feedback from
the FDA, Highland plans to initiate a pivotal trial with HLD-200 in
Methylphenidate is currently sold under the brand name Concerta by
Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company) and
Ritalin/Ritalin LA by Novartis Pharmaceuticals Corporation.
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is an emerging pharmaceutical company that,
through its wholly owned subsidiary Ironshore Pharmaceuticals &
Development, Inc., is leveraging its proprietary technologies to
optimize the delivery of previously approved drug products. The
Company's lead products, HLD-100 and HLD-200, are novel formulations of
the psychostimulants (amphetamine and methylphenidate, respectively)
used to treat ADHD and are being developed to address a prevalent unmet
medical need in the treatment of the disease - the lack of symptom
control during the early morning routine. The clinically meaningful
benefits of Highland's approach are targeted at helping ADHD patients
and their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District's Life
Sciences and Healthcare practice, which provides advisory services and
support to help Ontario life sciences companies grow and commercialize
This press release contains forward-looking information, which reflects
Highland's current expectations regarding future events.
Forward-looking information is based on a number of assumptions and is
subject to a number of risks and uncertainties, many of which are
beyond Highland's control that could cause actual results and events to
differ materially from those that are disclosed in or implied by such
forward-looking information. These forward-looking statements are made
as of the date of this press release and, except as expressly required
by applicable law, Highland assumes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
SOURCE Highland Therapeutics Inc.